Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups

by Ailawadhi, S, Swaika, A, Razavi, P, Yang, D, Chanan-Khan, A
Published 2014

Pediatric bony craniovertebral junction abnormalities: Institutional experience of 10 years

by Kale, S. S., Ailawadhi, Pankaj, Yerramneni, Vamsi Krishna, Chandra, P. S., Kumar, Rajender, Sharma, B. S., Mahapatra, A. K.
Published 2011

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics

by Razavi, P, Rand, K A, Cozen, W, Chanan-Khan, A, Usmani, S, Ailawadhi, S
Published 2013

Whole Exome Sequencing Leading to the Diagnosis of Dysferlinopathy with a Novel Missense Mutation (c.959G>C)

by Swaika, Abhisek, Boczek, Nicole J., Sood, Neha, Guthrie, Kimberly, Klee, Eric W., Agrawal, Ankit, Dimberg, Elliot L., Ailawadhi, Sikander
Published 2016

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

by Usmani, S Z, Sexton, R, Ailawadhi, S, Shah, J J, Valent, J, Rosenzweig, M, Lipe, B, Zonder, J A, Fredette, S, Durie, B, Hoering, A, Bartlett, B, Orlowski, R Z
Published 2015

Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications

by Paulus, Aneel, Chitta, Kasyapa S., Wallace, Paul K., Advani, Pooja P., Akhtar, Sharoon, Kuranz-Blake, Maja, Ailawadhi, Sikander, Chanan-Khan, Asher A.
Published 2015

Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

by Paulus, A, Akhtar, S, Caulfield, T R, Samuel, K, Yousaf, H, Bashir, Y, Paulus, S M, Tran, D, Hudec, R, Cogen, D, Jiang, J, Edenfield, B, Novak, A, Ansell, S M, Witzig, T, Martin, P, Coleman, M, Roy, V, Ailawadhi, S, Chitta, K, Linder, S, Chanan-Khan, A
Published 2016